|
Status |
Public on May 13, 2011 |
Title |
Under conditions of hormonal adjuvant treatment the estrogen receptor apoprotein supports breast cancer cell cycling through the retinoic acid receptor α1 apoprotein |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by array
|
Summary |
Under conditions of hormonal adjuvant treatment the estrogen receptor apoprotein supports breast cancer cell cycling through the retinoic acid receptor α1 apoprotein. Basal proliferation persisted in estrogen-sensitive breast cancer cells grown in hormone depleted conditioned media without or with 4-hydroxytamoxifen (OH-Tam). Downregulating ER using siRNA inhibited basal proliferation by promoting cell cycle arrest. The basal expression of RARα1, the only RARα isoform that was expressed in breast cancer cell lines and in most breast tumors, was supported by apo-ER but was unaffected by OH-Tam. The overlapping tamoxifen-insensitive gene regulation by apo-ER and apo-RARα1 comprised activation of mainly genes promoting cell cycle and mitosis and suppression of genes involved in growth inhibition.
|
|
|
Overall design |
Cells were plated at 20% confluence in low glucose phenol red free medium supplemented with 5% charcoal stripped FBS and glutamine 24h-48h prior to transfection. Treatment with vehicle, OH-Tam (100nM), or OH-Tam (500nM) was begun an additional 24h later. Cells were transfected with control siRNA, ERα siRNA or RARα siRNA.
|
|
|
Contributor(s) |
d’Alincourt Salazara M, Maya R, Mugdha P, Ivana K, Trumbly R, Iman M, Ratnam M |
Citation(s) |
21299862 |
|
Submission date |
Dec 23, 2010 |
Last update date |
Mar 25, 2019 |
Contact name |
Robert J Trumbly |
E-mail(s) |
robert.trumbly@utoledo.edu
|
Phone |
419-383-4347
|
Organization name |
University of Toledo
|
Department |
Biochemistry and Cancer Biology
|
Street address |
3000 Arlington Avenue
|
City |
Toledo |
State/province |
OH |
ZIP/Postal code |
43614 |
Country |
USA |
|
|
Platforms (1) |
GPL570 |
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array |
|
Samples (12)
|
GSM645710 |
MCF-7 +scrambled siRNA + vehicle rep1 (MD31) |
GSM645711 |
MCF-7 +scrambled siRNA + vehicle rep2 (MD32) |
GSM645712 |
MCF-7 +scrambled siRNA + 100 nM 4-hydroxytamoxifen rep1 (MD33) |
GSM645713 |
MCF-7 +scrambled siRNA + 100 nM 4-hydroxytamoxifen rep2 (MD34) |
GSM645714 |
MCF-7 +scrambled siRNA + 500 nM 4-hydroxytamoxifen rep1 (MD35) |
GSM645715 |
MCF-7 +scrambled siRNA + 500 nM 4-hydroxytamoxifen rep2 (MD36) |
GSM645716 |
MCF-7 +ER siRNA + vehicle rep1 (MD37) |
GSM645717 |
MCF-7 +ER siRNA + vehicle rep2 (MD38) |
GSM645718 |
MCF-7 +scrambled siRNA + vehicle rep1 (MD39) |
GSM645719 |
MCF-7 +scrambled siRNA + vehicle rep2 (MD40) |
GSM645720 |
MCF-7 + RARalpha siRNA + vehicle rep1 (MD41) |
GSM645721 |
MCF-7 + RARalpha siRNA + vehicle rep1 (MD42) |
|
Relations |
BioProject |
PRJNA135127 |